Companies
- Companies
- Company details
University of Nebraska Medical Center / UNeMed Corporation
Technology Marketing and Licensing for The University of Nebraska Medical Center
The company in detail
Profile
UNeMed is a service oriented corporation that functions as the interface between the University of Nebraska Medical Center (UNMC) and industry to promote UNMC technology development and economic development in Omaha. In cooperation with UNMC inventors and the Intellectual Property Office, UNeMed drives and facilitates the transfer of the technologies invented on campus into the marketplace. UNeMed Corporation was established in 1992 as a for-profit subsidiary of UNMC.
Partnering strategy/interests
The primary function of UNeMed is to advance technologies that originated at The University of Nebraska Medical Center. To this end, we seek both licensees as well as strategic partners to work with university scientists and clinicians to continue the development and commercialization of technologies.
Out-licensing
Radioimaging of the cancer cells allowing for a more clear diagnosis without significant adverse health effects. More
An improved animal restraint jacket designed to protect an implanted vascular catheter or other implanted device in the animal. More
Listing of all available antibodies More
A novel selective antimicrobial peptide based on human LL-37 by D-amino acid incorporation. More
This technology overcomes the amount of time required to culture and identify pathogens, using standard collection methods, is able to identify over 98% of relevant pathogens, and is a fully automated process More
These radioactive compounds have the very unique and unprecedented ability to bind very specifically and irreversibly to butyrylcholinesterase (BChE). More
Butyrylcholinesterase is commonly overexpressed in many types of cancer including ovarian cancer and gliomas. These compounds provide both therapeutic and diagnostic capabilities useful in the treatment of a variety of cancers. More
A cell line using human hepatocellular carcinoma (HepG2) cells stably expressing ADH (VA-13 cells) is a promising tool that will help further elucidate the mechanisms of ethanol-induced hepatocellular injury. More
Bacterial biofilms are becoming an increasing problem associated with catheters and other artificial implants. This novel method, for both preventing biofilm formation and treating established biofilms, has demonstrated significant efficacy in preventing More
A novel chemoenzymatic method for producing a key building block of Tamiflu (oseltamivir). More
The Gait-O-Gram can detect and analyze gait information from an individual and, through the use of fuzzy logic algorithms, determine the presence of neuromuscular symptoms. More
This technology describes a novel target for the treatment of obesity, providing for the discovery of additional inhibitors of Cyclophilin D, a well categorized, and highly relevant protein in obesity biology. More
A digital topography imaging system that allows for quality three dimensional topographic reconstruction of single crystals. More
Provides methods that allow for real time detection of endothelial dysfunction. More
An innovative surgical table that is capable of supporting small children up to 50 pounds in weight, and provides 360 degrees of horizontal rotation. More
Mouse model for the study of Janus Kinase signal transduction. More
This new laparoscope technology will improve efficiency and reduce overall costs of MIS for all parties involved. More
Site-specific localization and highly efficient drug delivery. More
The early detection and treatment of motor developmental delays in infants is critical to future motor skill function. More
Reperfusions can lead to severe damage in patients with heart attacks and strokes, the SOD-nanoparticles would be highly beneficial for use in hospitals for treating these patients. More
Monoclonal antibody for a novel HIV protein with potential diagnostic, prognostic, and therapeutic uses. More
Peptide vaccine to confer immunity to MUC1-expressing tumors More
This technology promises to be valuable in the study of MUC1-directed therapies for pancreatic cancer. More
Multiplex PCR based assay for the combined detection and diagnosis of Herpes viruses in patient samples. More
A novel series of NMDA receptor antagonists, which shows different selectivity for NMDA receptors than the previously described NMDA receptor antagonists. More
Currently no effective treatements exist for Parkinson's disease. This novel vaccine strategy provides a relatively safe and easy method to treat Parkinson's disease. More
The NF-kB pathway is associated with a variety of diseases such as cancer and diabetes. Many of these diseases do not currently have any effective therapies available. The lead compound 13-197 is a novel molecule for inhibiting the NF-kB pathway that is More
Cell line developed for studying the effects of FGFs. More
Recently characterized MUC17 gene highly specific for pancreatic cancer. More
Diagnostic and potential therapeutic applications for mucin gene 4 (MUC4). More
Allows greater flexibility for the dialysis patient. Current methods are dangerous and sometimes difficult for dialysis procedures. Can be used for antegrade arterial access from CFA approach. Other applications could be use for biliary and renal procedur More
The Tsg101 conditional mouse model will be useful for further understanding the cellular function of Tsg101. It will also provide a valuable tool for determining the role of Tsg101 in the development of a variety of diseases such as cancer or HIV. Further More
This technology provides a method to rapidly produce vaccines against a wide variety of antigens, to treat a number of diseases from infectious diseases to cancer. It is extremely versatile and could help revolutionize vaccine development. More
Press Releases
(19th Mar 2012) Butyrylcholinesterase-targeted radiopharmaceuticals developed at the University of Nebraska Medical Center show promise for treatment of cancer. More
Related Reports
Market Research Reports provided by reports.iptechex.com
May 2011 - 15 pages - $250
Jun 2011 - 17 pages - $125
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
May 2011 - 15 pages - $125
Dec 2010 - 32 pages - $500
Dec 2010 - 33 pages - $500
Dec 2010 - 63 pages - $1,000
Dec 2010 - 43 pages - $500
Dec 2010 - 31 pages - $500
Contact details
Head office
University of Nebraska Medical Center / UNeMed Corporation
UNeMed Corporation
986099 Nebraska Medical Center
Omaha, NE
Nebraska
68198-6099
Nebraska (USA)
UNeMed Corporation
986099 Nebraska Medical Center
Omaha, NE
Nebraska
68198-6099
Nebraska (USA)
Company figures
Formed: 1992
Related categories
- Industry sector
- Biotechnology
- Diagnostic
- Drug delivery
- Medical device
- Non-profit org./Government / Universities
- Pharmaceutical
- Research tools
- Therapeutic target
- Accident and Trauma
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Gastrointestinal
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Other therapeutic
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us